Kanjinti Side Effects

Generic name: trastuzumab

Medically reviewed by Drugs.com. Last updated on May 30, 2025.

Note: This document provides detailed information about Kanjinti Side Effects associated with trastuzumab. Some dosage forms listed on this page may not apply specifically to the brand name Kanjinti.

Applies to trastuzumab: intravenous powder for solution.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects.

Receiving this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant during treatment and for 7 months after the last dose. If you think you have become pregnant while receiving the medicine, tell your doctor right away.

Your doctor may test your heart before you start receiving trastuzumab-dttb injection and while you are getting treatments with this medicine. Contact your doctor right away if you experience any chest pain, increased coughing, trouble with breathing, a sudden difficulty with breathing at night, rapid weight gain, or abnormal swelling in your ankles or legs. These could be symptoms of a serious heart problem.

This medicine may cause infusion-related reactions, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you start to have a fever, chills or shaking, dizziness, trouble breathing, itching or rash, lightheadedness or fainting after receiving this medicine.

Serious lung or breathing problems may occur after you receive this medicine. Call your doctor right away if have changes in your breathing, chest tightness, or any type of breathing problem.

This medicine can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:

• If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.
• Check with your doctor immediately if you notice any unusual bleeding or bruising, black, tarry stools, blood in urine or stools, or pinpoint red spots on your skin.
• Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.
• Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.
• Be careful not to cut yourself when you are using sharp objects, such as a safety razor or fingernail or toenail cutters.
• Avoid contact sports or other situations where bruising or injury could occur.

Serious side effects of Kanjinti

Along with its needed effects, trastuzumab (the active ingredient contained in Kanjinti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking trastuzumab:

Other side effects of Kanjinti

Some side effects of trastuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

See also:

For healthcare professionals

Applies to trastuzumab: intravenous powder for injection.

General adverse events

The most common adverse events were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, stomatitis, weight loss, thrombocytopenia, mucosal inflammation, nasopharyngitis, dysgeusia, and myalgia.^[Ref]

Hematologic

• Very common (10% or more): Neutropenia (78%), leukopenia (52%), anemia (36%), febrile neutropenia (23%), thrombocytopenia (16%)
• Frequency not reported: Hypoprothrombinemia^[Ref]

Cardiovascular

• Very common (10% or more): LVEF decrease (44%), congestive heart failure (28%), cardiomyopathy (15%), peripheral edema (10%), tachycardia (10%)
• Common (1% to 10%): Hypertension, hypotension, asymptomatic cardiac dysfunction, ejection fraction decreased, palpitation, cardiac arrhythmia, cardiac failure, heart beat irregular, cardiac flutter, lymphedema, hot flush, thrombotic adverse event, supraventricular tachyarrhythmia, vasodilation
• Uncommon (0.1% to 1%): Ventricular dysfunction, pericardial effusion
• Frequency not reported: Cardiogenic shock, pericarditis, bradycardia, gallop rhythm present, S3 gallop^[Ref]

Hypersensitivity

• Very common (10% or more): Infusion-related reactions (54%)
• Common (1% to 10%): Hypersensitivity, allergic reaction
• Frequency not reported: Anaphylactic reaction, anaphylactic shock^[Ref]

Respiratory

• Very common (10% or more): Cough (43%), dyspnea (42%), rhinitis (22%), Grade 2 to 5 pulmonary toxicity (14%), nasopharyngitis (13%), wheezing, epistaxis, rhinorrhea
• Common (1% to 10%): Pharyngolaryngeal pain, sinusitis, epistaxis, upper respiratory infection, rhinitis, asthma, lung disorder, pleural effusion
• Uncommon (0.1% to 1%): Pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis
• Frequency not reported: Pulmonary insufficiency, pulmonary fibrosis, respiratory distress, respiratory failure, lung infiltration, acute pulmonary edema, acute respiratory distress syndrome, bronchospasm, hypoxia, oxygen saturation decreased, laryngeal edema, pulmonary edema, orthopnea
• Postmarketing reports: Bronchospasm, hypoxia, pleural effusions, non-cardiogenic pulmonary edema^[Ref]

Immunologic

• Very common (10% or more): Infection (47%), herpes simplex (38%), antibody to trastuzumab (the active ingredient contained in Kanjinti) (15%), flu syndrome (12%)
• Common (1% to 10%): Neutropenic sepsis, postoperative wound infection, herpes zoster
• Uncommon (0.1% to 1%): Sepsis^[Ref]

Renal

• Very common (10% or more): Renal impairment/failure (18%)
• Common (1% to 10%): Grade 3 or 4 renal failure, renal disorder, hyperbilirubinemia
• Frequency not reported: Glomerulonephritis membranous, glomerulonephropathy, renal failure
• Postmarketing reports: Nephrotic syndrome with pathological evidence of glomerulopathy^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (76%), vomiting (53%), diarrhea (45%), abdominal pain (34%), stomatitis (24%), anorexia (14%)
• Common (1% to 10%): Constipation, dyspepsia, dysphagia, lip swelling, pancreatitis, hemorrhoids, dry mouth^[Ref]

Nervous system

• Very common (10% or more): Headache (44%), asthenia (42%), fatigue (35%), insomnia (29%), dizziness (24%), paresthesia (23%), peripheral neuritis (23%), neuropathy (13%), dysgeusia (10%), dizziness (13%), tremor, hypoesthesia
• Common (1% to 10%): Hypertonia, somnolence, ataxia
• Rare (less than 0.1%): Paresis
• Frequency not reported: Brain edema^[Ref]

Dermatologic

• Very common (10% or more): Rash (38%), nail changes (12%), acne (11%), rash/desquamation (11%), erythema, swelling face, palmar-plantar erythrodysesthesia syndrome, alopecia
• Common (1% to 10%): Pruritus, dry skin, ecchymosis, hyperhidrosis, maculopapular rash, onychoclasis, dermatitis, contusion, skin infection, erysipelas, cellulitis
• Uncommon (0.1% to 1%): Urticaria
• Frequency not reported: Angioedema^[Ref]

Musculoskeletal

• Very common (10% or more): Arthralgia (37%), back pain (34%), bone pain (24%), muscle tightness, myalgia
• Common (1% to 10%): Muscle spasm, neck pain, pain in extremity, arthritis^[Ref]

Metabolic

• Very common (10% or more): Anorexia (31%), hypokalemia (28%), weight loss (23%)
• Frequency not reported: Hyperkalemia
• Postmarketing reports: Volume overload^[Ref]

Other

• Very common (10% or more): Asthenia (62%), pain (61%), fever (56%), chills (41%), accidental injury (13%)
• Common (1% to 10%): Malaise
• Uncommon (0.1% to 1%): Deafness
• Rare (less than 0.1%): Sudden death
• Postmarketing reports: Oligohydramnios or oligohydramnios sequence (including pulmonary hypoplasia, skeletal abnormalities, and neonatal death)^[Ref]

Hepatic

• Common (1% to 10%): Hepatocellular injury, hepatitis, liver tenderness
• Rare (less than 0.1%): Jaundice
• Frequency not reported: Hepatic failure^[Ref]

Ocular

• Very common (10% or more): Conjunctivitis, lacrimation increased
• Common (1% to 10%): Dry eye
• Frequency not reported: Papilledema, retinal hemorrhage^[Ref]

Genitourinary

• Common (1% to 10%): Breast inflammation/mastitis, urinary tract infection, cystitis^[Ref]

Psychiatric

• Very common (10% or more): Depression (20%), insomnia (14%)
• Common (1% to 10%): Anxiety, thinking abnormal
• Uncommon (0.1% to 1%): Depression^[Ref]

Endocrine

• Uncommon (0.1% to 1%): Autoimmune thyroiditis^[Ref]

Oncologic

• Frequency not reported: Malignant neoplasm progression, neoplasm progression^[Ref]

Frequently asked questions

• What are biosimilar drugs and how do they compare to biologics?
• What are the biosimilars of Herceptin?
• How soon can you start chemo after port placement?
• How long can you stay on Herceptin and Perjeta?
• What happens after Herceptin treatment?
• How long can I stay on Herceptin?
• What is TDM1 chemotherapy?
• What are biologic drugs and how do they work?
• What biosimilars have been approved in the United States?

Further information

Kanjinti side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer